BPC-157 Australia: Research Guide, Purity & COA
Published 9 June 2026
Compiled by the APL Research TeamSourced directly from peer-reviewed pharmacological literature and clinical guidelines.
Key Takeaways
- Expert Insight: BPC-157 is a stable synthetic pentadecapeptide derived from human gastric juice protein, studied primarily in angiogenesis and tissue-repair research models.
- Quality Assurance: Every batch ships with a Certificate of Analysis (HPLC + MS); select batches receive independent third-party purity verification.
- Research Use Only: BPC-157 is supplied for in-vitro laboratory research — not for human or animal consumption.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a partial sequence of a protein found in human gastric juice. It has been the subject of extensive preclinical research since the early 1990s, largely because of an unusual property for a peptide of its size: stability in gastric acid. That stability, together with its broad cytoprotective profile across animal models, has made it a compound of sustained interest in gastrointestinal and tissue-repair research.
Australian Peptide Labs supplies BPC-157 in Australia as a research chemical for in-vitro laboratory work. This page is an overview and sourcing guide; for the underlying biochemistry, see the deep-dive article linked below.
Molecular Profile
| Property | Value |
|---|---|
| Also Known As | PL 14736, Bepecin, BPC 15 |
| Type | Synthetic pentadecapeptide (15 amino acids) |
| CAS Number | 137525-51-0 |
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ |
| Molecular Weight | 1419.53 Da |
| Appearance | Lyophilised white powder |
| Format (research) | Subcutaneous administration in animal models |
Research Applications
Across the published literature, BPC-157 is studied along three interconnected lines of inquiry:
- Angiogenesis — in-vitro work using human umbilical vein endothelial cells (HUVECs) reports enhanced endothelial proliferation, migration, and tube formation, with upregulation of VEGF-receptor expression.
- Tissue repair — animal models examine tendon-to-bone healing, muscle-fibre regeneration after crush injury, and ligament repair.
- Gastrointestinal cytoprotection — the "body protection" designation reflects accelerated healing of gastric ulcers, intestinal anastomoses, and fistulas in rodent models, alongside bidirectional modulation of the nitric oxide (NO) system.
These are preclinical and in-vitro findings only and do not establish any effect in humans. For the full mechanistic detail — including the NO-homeostasis and cytoprotective pathways — see our deep-dive article: BPC-157: Mechanisms and Research Applications. Researchers studying combined tissue-repair models may also be interested in BPC-157 and TB-500: Complementary Mechanisms in Tissue Repair Research.
Quality & Certificate of Analysis
Every batch of BPC-157 is analysed in-house by high-performance liquid chromatography (HPLC) and mass spectrometry (MS), and ships with a batch-specific Certificate of Analysis (COA). HPLC quantifies purity (we specify ≥98%, the High-Tier Research Grade standard), while MS confirms the molecular identity of the peptide. Select batches also undergo independent, third-party purity verification.
Learn more: Every BPC-157 batch certificate · How purity is verified · How to read a COA.
Handling, Reconstitution & Storage
BPC-157 is supplied lyophilised and is comparatively robust, but it should still be handled like any research peptide. Store the lyophilised powder at -20°C, reconstitute with bacteriostatic water following standard protocols, and keep the reconstituted solution refrigerated (2-8°C), protected from light, with freeze-thaw cycles minimised.
Sourcing BPC-157 for Research in Australia
Australian Peptide Labs supplies BPC-157 as a research chemical for in-vitro laboratory use only. Orders are dispatched same day from within Australia with a Certificate of Analysis included, with cold-chain handling where required. BPC-157 is not approved for human therapeutic use and is not for human or animal consumption; researchers are responsible for compliance with TGA regulations and institutional protocols.
View BPC-157 product details & current purity →
Frequently Asked Questions
Is BPC-157 legal to buy in Australia? BPC-157 is supplied strictly as a research chemical for in-vitro laboratory use. It is not approved for human therapeutic use in Australia and is not for human or animal consumption. Researchers are responsible for compliance with Therapeutic Goods Administration (TGA) regulations and their institution's protocols.
How is the purity of BPC-157 verified? Every batch is analysed in-house by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) and ships with a Certificate of Analysis. Select batches also undergo independent, third-party purity verification.
What is BPC-157 studied for in research? In published preclinical and in-vitro work, BPC-157 has been studied as a model compound in angiogenesis (the formation of new blood vessels), tendon, ligament and muscle repair, and gastrointestinal cytoprotection. These are laboratory research findings only and do not establish any effect in humans.
Does Australian Peptide Labs provide dosing guidance? No. As these compounds are supplied for laboratory research only, we do not provide dosing or administration protocols. Our research library covers reconstitution and concentration calculations for in-vitro work.
How should BPC-157 be stored and reconstituted? BPC-157 ships as a lyophilised powder and is stable at -20°C before reconstitution. It is unusually stable for a peptide of its size, but reconstituted solution should be kept at 2-8°C, protected from light, and used within its stability window. See our reconstitution and storage guides for full protocols.
References
- Sikiric, P. et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design, 2011. — PubMed: 21548867
- Chang, C.H. et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology (Bethesda, Md. : 1985), 2011. — PubMed: 21030672
- Seiwerth, S. et al. "BPC 157 and blood vessels." Current Pharmaceutical Design, 2014. — PubMed: 23782145
- Sikiric, P. et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Current Neuropharmacology, 2016. — PubMed: 27138887
⚠️ Medical & Regulatory Disclaimer:The information provided in this academic article is intended exclusively for educational and laboratory research purposes. It does NOT constitute medical advice. Compounds discussed are strictly for in-vitro research and development only, and are not intended for human consumption, veterinary use, or clinical treatment. Always adhere to Australian Therapeutic Goods Administration (TGA) regulations and your institution's ethical guidelines when handling research chemicals.